MK-4716

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-4716, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) [Phase 1]